Lymphoma Clinical Trials in Chicago

Showing 241-260 of 559 trials

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

NCT03932279

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.

Cutaneous T Cell Lymphoma

Northwestern University300 participantsStarted Jan 2019

Chicago, Illinois, United States

TERMINATEDPhase 12.2 miles

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

Celgene174 participantsStarted Dec 2013

Stanford, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +13 more locations

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Lymphoma Trials in Other Cities

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Other Conditions in Chicago